Shire (SHPG) Earning Somewhat Positive Press Coverage, Report Finds

Press coverage about Shire (NASDAQ:SHPG) has trended somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Shire earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.923087278091 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

SHPG stock opened at $157.79 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.55 and a debt-to-equity ratio of 0.46. The firm has a market cap of $46,571.37, a price-to-earnings ratio of 10.33, a PEG ratio of 1.21 and a beta of 1.31. Shire has a fifty-two week low of $123.73 and a fifty-two week high of $192.15.

Shire (NASDAQ:SHPG) last posted its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share for the quarter, topping the consensus estimate of $3.86 by $0.12. The firm had revenue of $4.14 billion for the quarter. Shire had a return on equity of 14.19% and a net margin of 28.17%. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.37 EPS. equities analysts expect that Shire will post 15.23 EPS for the current fiscal year.

The company also recently disclosed a semiannual dividend, which will be paid on Tuesday, April 24th. Shareholders of record on Friday, March 9th will be given a dividend of $0.8937 per share. This is a boost from Shire’s previous semiannual dividend of $0.15. The ex-dividend date is Thursday, March 8th. This represents a yield of 1.33%. Shire’s dividend payout ratio (DPR) is presently 6.93%.

A number of brokerages have recently issued reports on SHPG. BidaskClub upgraded Shire from a “sell” rating to a “hold” rating in a research note on Friday, March 30th. Zacks Investment Research upgraded Shire from a “sell” rating to a “hold” rating in a research note on Friday, March 23rd. Bank of America reiterated a “buy” rating on shares of Shire in a research note on Wednesday, March 28th. ValuEngine cut Shire from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Cantor Fitzgerald set a $222.00 price objective on Shire and gave the stock a “buy” rating in a research note on Wednesday, March 28th. Nine equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $204.00.

COPYRIGHT VIOLATION NOTICE: This story was posted by BBNS and is the property of of BBNS. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://baseballnewssource.com/2018/04/06/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-shire-shpg-stock-price/2031025.html.

About Shire

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.

Insider Buying and Selling by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings


Leave a Reply

 
© 2006-2018 BBNS.